Catalyst Pharmaceuticals to Report First Quarter 2025 Financial Results on May 7, 2025

Rhea-AI Summary

Catalyst Pharmaceuticals (CPRX), a commercial-stage biopharmaceutical company specializing in rare and difficult-to-treat diseases, has scheduled its first quarter 2025 financial results release for May 7, 2025, after market close.

The company will host a conference call and webcast the following day, May 8, 2025, at 8:30 AM ET. During this event, management will discuss financial results and provide a business update. Investors can access the webcast through the Investors section of Catalyst's website, with a replay available for at least 30 days after the event.

The Company will Host a Conference Call and Webcast on May 8, 2025, at 8:30 AM ET

CORAL GABLES, Fla., April 22, 2025 (GLOBE NEWSWIRE) --  Catalyst Pharmaceuticals, Inc. ("Catalyst" or "Company") (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on in-licensing, developing, and commercializing novel medicines for patients living with rare and difficult-to-treat diseases, today announced that it will release its first quarter 2025 financial results after the market close on Wednesday, May 7, 2025.

Catalyst's management team will host a conference call and webcast on Thursday, May 8, 2025, at 8:30 AM ET to discuss the Company's financial results and provide a business update.

Conference Call & Webcast Details
Date:  Time:    US/Canada Dial-in Number: International Dial-in Number:	May 8, 2025 8:30 AM ET (833) 316-2483 (785) 838-9284

The webcast will be accessible under the Investors section on the Company's website at www.catalystpharma.com. A webcast replay will be available on Catalyst’s website for at least 30 days following the date of the event.

About Catalyst Pharmaceuticals
Catalyst Pharmaceuticals, Inc. (Nasdaq: CPRX), is a biopharmaceutical company committed to improving the lives of patients with rare diseases. With a proven track record of bringing life-changing treatments to the market, we focus on in-licensing, commercializing, and developing innovative therapies. Guided by our deep commitment to patient care, we prioritize accessibility, ensuring patients receive the care they need through a comprehensive suite of support services designed to provide seamless access and ongoing assistance. Catalyst maintains a well-established U.S. presence while actively seeking to expand its global commercial footprint through strategic partnerships. Catalyst, headquartered in Coral Gables, Fla., was recognized on the Forbes 2025 list as one of America's Most Successful Mid-Cap Companies and on the 2024 Deloitte Technology Fast 500™ list as one of North America’s Fastest-Growing Companies.

For more information, please visit Catalyst's website at www.catalystpharma.com. 

Forward-Looking Statements
This press release contains forward-looking statements, as that term is defined in the Private Securities Litigation Reform Act of 1995. Forward-looking statements involve known and unknown risks and uncertainties, which may cause Catalyst's actual results in future periods to differ materially from forecasted results. A number of factors, including those factors described in Catalyst's Annual Report on Form 10-K for the fiscal year 2024 and its subsequent filings with the U.S. Securities and Exchange Commission (“SEC”), could adversely affect Catalyst. Copies of Catalyst's filings with the SEC are available from the SEC, may be found on Catalyst's website, or may be obtained upon request from Catalyst. Catalyst does not undertake any obligation to update the information contained herein, which speaks only as of this date.

Source: Catalyst Pharmaceuticals, Inc.

Investor Contact
Mary Coleman, Catalyst Pharmaceuticals, Inc.
(305) 420-3200
ir@catalystpharma.com

Media Contact
David Schull, Russo Partners
(858) 717-2310
david.schull@russopartnersllc.com

FAQ

When will Catalyst Pharmaceuticals (CPRX) release Q1 2025 earnings?

Catalyst Pharmaceuticals will release Q1 2025 earnings after market close on Wednesday, May 7, 2025.

How can investors join Catalyst Pharmaceuticals' Q1 2025 earnings call?

Investors can join via phone (US/Canada: 833-316-2483, International: 785-838-9284) or webcast through Catalyst's website on May 8, 2025, at 8:30 AM ET.

Where can I find the replay of CPRX's Q1 2025 earnings webcast?

The webcast replay will be available in the Investors section of www.catalystpharma.com for at least 30 days following the event.

What is Catalyst Pharmaceuticals' main business focus?

Catalyst Pharmaceuticals is a commercial-stage biopharmaceutical company focused on in-licensing, developing, and commercializing novel medicines for rare and difficult-to-treat diseases.